Cargando…
Ivermectin Treatment Coverage Validation in Two Onchocerciasis Endemic Districts in Ethiopia: A Community-Based Cross-Sectional Study, 2019
BACKGROUND: Onchocerciasis is the second leading cause of blindness globally next to trachoma, thus eliminating the infection is an important health priority. It is estimated that 15.7 million people are at risk of infection in different parts of Ethiopia. Mass drug administration with ivermectin at...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822083/ https://www.ncbi.nlm.nih.gov/pubmed/33500622 http://dx.doi.org/10.2147/JMDH.S288239 |
_version_ | 1783639557777915904 |
---|---|
author | Churko, Chuchu Yihune, Manaye Teshome, Abinet Chisha, Yilma Getachew, Birhanu Sleshi, Markos Asfaw, Mekuria Asnakew Shibiru, Tamiru Ayele, Nebiyu Negussu Seife, Fikre Zerdo, Zerihun Bekele Kassahun, Alemayehu |
author_facet | Churko, Chuchu Yihune, Manaye Teshome, Abinet Chisha, Yilma Getachew, Birhanu Sleshi, Markos Asfaw, Mekuria Asnakew Shibiru, Tamiru Ayele, Nebiyu Negussu Seife, Fikre Zerdo, Zerihun Bekele Kassahun, Alemayehu |
author_sort | Churko, Chuchu |
collection | PubMed |
description | BACKGROUND: Onchocerciasis is the second leading cause of blindness globally next to trachoma, thus eliminating the infection is an important health priority. It is estimated that 15.7 million people are at risk of infection in different parts of Ethiopia. Mass drug administration with ivermectin at community and school level is the basis for control and elimination of onchocerciasis. This study was aimed at validating onchocerciasis treatment coverage in the selected districts of Ethiopia. METHODS: A community-based cross-sectional study was employed in Itang special and Wombera districts of Ethiopia, from April 1 to 30, 2019 G.C. We used a coverage validation survey builder tool to compute sample size. Individuals aged five years old and above were eligible population. Data were entered into Microsoft Excel and exported to STATA 14 for cleaning and analyses. A chi-square test was used to note statistical association of the outcome variables with independent variables. MAIN FINDINGS: A total of 3765 individuals were interviewed. Of these, 3244 were offered onchocerciasis treatment. The overall treatment coverage of onchocerciasis in the two selected districts of Ethiopia was 85.9% of the eligible population (3235/3765) (95% CI, 84.8%, 87%). There was significant difference between the two districts in terms of ivermectin offering (X(2)=70.467, P<0.001). School attendance was also significantly associated with treatment offering and swallowing status (X(2)=77.29, P<0.001; and X(2)=30.581, P<0.001). The main reported reasons for not being offered ivermectin were “being absent” (40.86%) and “not knowing about the mass drug administration” (MDA) (25.29%). CONCLUSION: In conclusion, the treatment coverage of onchocerciasis in this survey was higher than minimum national desired therapeutic coverage. Treatment coverage in Wombera was higher than Itang special district. In addition, children who attended school had a higher chance of swallowing the drug. |
format | Online Article Text |
id | pubmed-7822083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78220832021-01-25 Ivermectin Treatment Coverage Validation in Two Onchocerciasis Endemic Districts in Ethiopia: A Community-Based Cross-Sectional Study, 2019 Churko, Chuchu Yihune, Manaye Teshome, Abinet Chisha, Yilma Getachew, Birhanu Sleshi, Markos Asfaw, Mekuria Asnakew Shibiru, Tamiru Ayele, Nebiyu Negussu Seife, Fikre Zerdo, Zerihun Bekele Kassahun, Alemayehu J Multidiscip Healthc Original Research BACKGROUND: Onchocerciasis is the second leading cause of blindness globally next to trachoma, thus eliminating the infection is an important health priority. It is estimated that 15.7 million people are at risk of infection in different parts of Ethiopia. Mass drug administration with ivermectin at community and school level is the basis for control and elimination of onchocerciasis. This study was aimed at validating onchocerciasis treatment coverage in the selected districts of Ethiopia. METHODS: A community-based cross-sectional study was employed in Itang special and Wombera districts of Ethiopia, from April 1 to 30, 2019 G.C. We used a coverage validation survey builder tool to compute sample size. Individuals aged five years old and above were eligible population. Data were entered into Microsoft Excel and exported to STATA 14 for cleaning and analyses. A chi-square test was used to note statistical association of the outcome variables with independent variables. MAIN FINDINGS: A total of 3765 individuals were interviewed. Of these, 3244 were offered onchocerciasis treatment. The overall treatment coverage of onchocerciasis in the two selected districts of Ethiopia was 85.9% of the eligible population (3235/3765) (95% CI, 84.8%, 87%). There was significant difference between the two districts in terms of ivermectin offering (X(2)=70.467, P<0.001). School attendance was also significantly associated with treatment offering and swallowing status (X(2)=77.29, P<0.001; and X(2)=30.581, P<0.001). The main reported reasons for not being offered ivermectin were “being absent” (40.86%) and “not knowing about the mass drug administration” (MDA) (25.29%). CONCLUSION: In conclusion, the treatment coverage of onchocerciasis in this survey was higher than minimum national desired therapeutic coverage. Treatment coverage in Wombera was higher than Itang special district. In addition, children who attended school had a higher chance of swallowing the drug. Dove 2021-01-18 /pmc/articles/PMC7822083/ /pubmed/33500622 http://dx.doi.org/10.2147/JMDH.S288239 Text en © 2021 Churko et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Churko, Chuchu Yihune, Manaye Teshome, Abinet Chisha, Yilma Getachew, Birhanu Sleshi, Markos Asfaw, Mekuria Asnakew Shibiru, Tamiru Ayele, Nebiyu Negussu Seife, Fikre Zerdo, Zerihun Bekele Kassahun, Alemayehu Ivermectin Treatment Coverage Validation in Two Onchocerciasis Endemic Districts in Ethiopia: A Community-Based Cross-Sectional Study, 2019 |
title | Ivermectin Treatment Coverage Validation in Two Onchocerciasis Endemic Districts in Ethiopia: A Community-Based Cross-Sectional Study, 2019 |
title_full | Ivermectin Treatment Coverage Validation in Two Onchocerciasis Endemic Districts in Ethiopia: A Community-Based Cross-Sectional Study, 2019 |
title_fullStr | Ivermectin Treatment Coverage Validation in Two Onchocerciasis Endemic Districts in Ethiopia: A Community-Based Cross-Sectional Study, 2019 |
title_full_unstemmed | Ivermectin Treatment Coverage Validation in Two Onchocerciasis Endemic Districts in Ethiopia: A Community-Based Cross-Sectional Study, 2019 |
title_short | Ivermectin Treatment Coverage Validation in Two Onchocerciasis Endemic Districts in Ethiopia: A Community-Based Cross-Sectional Study, 2019 |
title_sort | ivermectin treatment coverage validation in two onchocerciasis endemic districts in ethiopia: a community-based cross-sectional study, 2019 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822083/ https://www.ncbi.nlm.nih.gov/pubmed/33500622 http://dx.doi.org/10.2147/JMDH.S288239 |
work_keys_str_mv | AT churkochuchu ivermectintreatmentcoveragevalidationintwoonchocerciasisendemicdistrictsinethiopiaacommunitybasedcrosssectionalstudy2019 AT yihunemanaye ivermectintreatmentcoveragevalidationintwoonchocerciasisendemicdistrictsinethiopiaacommunitybasedcrosssectionalstudy2019 AT teshomeabinet ivermectintreatmentcoveragevalidationintwoonchocerciasisendemicdistrictsinethiopiaacommunitybasedcrosssectionalstudy2019 AT chishayilma ivermectintreatmentcoveragevalidationintwoonchocerciasisendemicdistrictsinethiopiaacommunitybasedcrosssectionalstudy2019 AT getachewbirhanu ivermectintreatmentcoveragevalidationintwoonchocerciasisendemicdistrictsinethiopiaacommunitybasedcrosssectionalstudy2019 AT sleshimarkos ivermectintreatmentcoveragevalidationintwoonchocerciasisendemicdistrictsinethiopiaacommunitybasedcrosssectionalstudy2019 AT asfawmekuriaasnakew ivermectintreatmentcoveragevalidationintwoonchocerciasisendemicdistrictsinethiopiaacommunitybasedcrosssectionalstudy2019 AT shibirutamiru ivermectintreatmentcoveragevalidationintwoonchocerciasisendemicdistrictsinethiopiaacommunitybasedcrosssectionalstudy2019 AT ayelenebiyunegussu ivermectintreatmentcoveragevalidationintwoonchocerciasisendemicdistrictsinethiopiaacommunitybasedcrosssectionalstudy2019 AT seifefikre ivermectintreatmentcoveragevalidationintwoonchocerciasisendemicdistrictsinethiopiaacommunitybasedcrosssectionalstudy2019 AT zerdozerihun ivermectintreatmentcoveragevalidationintwoonchocerciasisendemicdistrictsinethiopiaacommunitybasedcrosssectionalstudy2019 AT bekelekassahunalemayehu ivermectintreatmentcoveragevalidationintwoonchocerciasisendemicdistrictsinethiopiaacommunitybasedcrosssectionalstudy2019 |